# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-053921
Filing Date
2024-05-07
Accepted
2024-05-07 07:02:51
Documents
73
Period of Report
2024-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | apls-20240331.htm iXBRL | 10-Q | 1591162
2 | EX-31.1 | apls-ex31_1.htm | EX-31.1 | 15851
3 | EX-31.2 | apls-ex31_2.htm | EX-31.2 | 15075
4 | EX-32.1 | apls-ex32_1.htm | EX-32.1 | 8349
5 | EX-32.2 | apls-ex32_2.htm | EX-32.2 | 8441
| Complete submission text file | 0000950170-24-053921.txt |  | 7413648

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | apls-20240331.xsd | EX-101.SCH | 1230803
77 | EXTRACTED XBRL INSTANCE DOCUMENT | apls-20240331_htm.xml | XML | 1199731

Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

EIN.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38276 | Film No.: 24919548
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)